Adaptive Biotechnologies: Tycho Peterson, Kyle Piskel
Tycho Peterson is stepping down as CFO of Adaptive Biotechnologies in order to take up a post as managing director at Jefferies. He is succeeded by Kyle Piskel, currently Adaptive's principal accounting officer. Piskel has been with the company for eight years, serving previously as its interim CFO in 2022.
Zephyr AI: Rachel Brake
Precision medicine technology company Zephyr AI has appointed Rachael Brake as its CSO. Brake is the former CSO at Corbus Pharmaceuticals. Prior to this, she spent 11 years at Takeda Oncology, most recently as head of US medical affairs, oncology, and earlier as global program VP and associate director in translational research. Brake began her career as a research scientist at the Western Australian Institute for Medical Research before moving to Amgen in the US where she worked as a principal scientist. She holds a bachelor of science degree in molecular biology and biochemistry from the Australian National University and a PhD from the University of Western Australia.
Sail Biomedicines: Wendy Chung
Wendy Chung has joined the board of directors of Sail Biomedicines, a company developing RNA-based programmable therapeutics. She is chief of the department of pediatrics at Boston Children's Hospital, a faculty member at Harvard Medical School, and president of the Children's Hospital Pediatric Associates. She is also principal investigator of the GUARDIAN newborn study that is testing the utility of whole-genome sequencing for newborn screening.
Nucleai: Noga Yerushalmi
Noga Yerushalmi has joined the board of directors of spatial biology informatics firm Nucleai in connection with the company's recent financing. He is investment director at M Ventures, the venture capital arm of Merck KGaA, which invested $14 million in Nucleai.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.